Efficacy, tolerability, and safety of Efsubaglutide Alfa in participants with obesity or overweight ( LIGHT 1): A randomized, double‐blind, placebo‐controlled, ascending‐dose phase 2a trial

Ähnliche Einträge

• Efsubaglutide alfa in adults with overweight or obesity: Protocol for a seamless, adaptive phase 2b/3 randomized, double‐blind, placebo‐controlled trial ( LIGHT 2)
  von: Weiping Jia, et al.
  Veröffentlicht: (2026)
• Efficacy and safety of Efsubaglutide Alfa in “overrun” patients in the SUPER2 trial: A post‐hoc analysis for comprehensive evaluation
  von: Weiping Jia, et al.
  Veröffentlicht: (2025)
• Efficacy and safety of intragastric expandable oral capsules in adults with overweight or obesity: A randomized, double‐blind, placebo‐controlled trial
  von: Difei Lu, et al.
  Veröffentlicht: (2024)
• Efsubaglutide Alfa attenuates metabolic dysfunction‐associated steatohepatitis in mice with improvements in second harmonic generation‐derived fibrosis features
  von: Yahao Wang, et al.
  Veröffentlicht: (2026)
• A randomized, double‐blind, placebo‐controlled, multiple ascending dose study to evaluate the efficacy, pharmacokinetics, and safety of ABBV‐916 in adults with early Alzheimer’s disease
  von: Shau Yu Lynch, et al.
  Veröffentlicht: (2025)